First-line PARP inhibition in ovarian cancer - standard of care for all?

Nat Rev Clin Oncol. 2020 Mar;17(3):136-137. doi: 10.1038/s41571-020-0335-9.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Clinical Trials as Topic
  • Female
  • Humans
  • Mutation
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / epidemiology
  • Ovarian Neoplasms / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Progression-Free Survival
  • Standard of Care

Substances

  • Antineoplastic Agents
  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Poly(ADP-ribose) Polymerase Inhibitors